Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sezary Syndrome 2Mycosis Fungoides 2Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Hepatocellular 1Carcinoma 1Advanced Solid Tumors 1

Interventions

romidepsin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Vincristine 4Gemcitabine 4Doxorubicin 4Cyclophosphamide 4Prednisone 3Lenalidomide 3Azacitidine 310-propargyl-10-deazaaminopterin 3pembrolizumab 2ixazomib 2fludarabine phosphate 2copanlisib 2Whole-Body Irradiation 2Vitamin B 12 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mycophenolic Acid 2Folic Acid 2Etoposide 2Dexamethasone 2Cyclosporine 2Bortezomib 2venetoclax 1tislelizumab 1tazemetostat 1relatlimab 1prednisolone phosphate 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell, Peripheral × mogamulizumab × Clear all
NCT00888927 2024-04-25

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
42 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡